Australia and Southeast Asia Strengthen Clinical Trials Collaboration at CTFA 2026

• Australia strengthened clinical trial partnerships with Southeast Asian stakeholders during Clinical Trials Festival Asia (CTFA) 2026 in Singapore.

• The collaboration focused on cross-border trials, regulatory engagement, and expanding clinical research capacity across the region. 

Austrade strengthened collaboration between Australia and Southeast Asia during Clinical Trials Festival Asia (CTFA) 2026 in Singapore, bringing together clinical research organizations (CROs), biotechnology companies, research institutions, and healthcare providers to support cross-border clinical trials. The initiative aimed to expand partnerships and enhance regional clinical development capabilities.

Austrade supported an Australian delegation of CROs, clinical trial sites, contract development and manufacturing organizations (CDMOs), and biotechnology companies. The discussions focused on strengthening engagement with Southeast Asian hospitals, regulators, and research institutions to improve trial delivery and support multi-country clinical development strategies.

The collaboration highlighted complementary regional strengths. Australia offers experienced investigators, established research infrastructure, and streamlined regulatory pathways, while Southeast Asia provides large and diverse patient populations and growing clinical research capacity. The combined capabilities are expected to support faster recruitment and broader trial participation.

The engagement forms part of Australia’s broader strategy to position itself as a preferred destination for clinical trials while strengthening regional partnerships. As global sponsors increasingly adopt multi-country trial strategies, collaboration between Australia and Southeast Asia is expected to play a growing role in clinical development planning.

“By strengthening partnerships between Australia and Southeast Asia, we can support clinical trial delivery at scale while maintaining high standards of quality and compliance, benefiting sponsors and patients across the region.”

Austrade official Statement